(Q33533553)

English

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

scientific article

Statements

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H (English)
0 references
0 references
0 references
Matthias Pauschinger

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit